 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Trials
Diverse characterised Disease Stated Materials can be aliquoted for different clinical trials and specific evaluation projects.
| Code | Product Name |
| DITR001 | Apolipoprotein A1 (APOA1) |
| DITR002 | Apolipoprotein B (APOB) |
| DITR003 | Cancer Antigen AFP |
| DITR004 | Cancer Antigen CA125 |
| DITR005 | Cancer Antigen CA153 |
| DITR006 | Cancer Antigen CA199 |
| DITR007 | Cancer Antigen CA724 |
| DITR008 | Cancer Antigen CEA |
| DITR009 | Cancer Antigen PSA |
| DITR010 | Cancer Antigen Squamous Cell Carcinoma (SCC) |
| DITR011 | Complement 3 (C3) |
| DITR012 | Complement 4 (C4) |
| DITR013 | Development：Acute Pancreatitis |
| DITR014 | Development：Alcoholic Liver Disease |
| DITR015 | Development：Breast Cancer |
| DITR016 | Development：Cervical Cancer |
| DITR017 | Development：Chronic Pancreatitis |
| DITR018 | Development：Colorectal Cancer |
| DITR019 | Development：Esophagal Cancer |
| DITR020 | Development：Grave's Disease |
| DITR021 | Development：Hashimoto |
| DITR022 | Development：Head and Neck Cancer |
| DITR023 | Development：Liver Cirrhosis |
| DITR024 | Development：Lung Cancer (NSCLC/SCLC) |
| DITR025 | Development：Neuroblastoma |
| DITR026 | Development：Non-Alcoholic Fatty Liver (NAFL) |
| DITR027 | Development：Non-Alcoholic Steatohepatitis (NASH) |
| DITR028 | Development：Ovarian Cancer |
| DITR029 | Development：Pancreatic Cancer |
| DITR030 | Development：Prostate Cancer |
| DITR031 | Development：Stomach Cancer |
| DITR032 | Development：Thyroid Cancer |
| DITR033 | Hepatitis A Virus (HAV) Antigen/IgG/IgM |
| DITR034 | Hepatitis B Surface (HBs) Antibody/Antigen |
| DITR035 | Hepatitis C Antigen (HCV) Antibody/Antigen |
| DITR036 | Hepatitis D Virus (HDV) Antibody/Antigen |
| DITR037 | Hepatitis E Virus (HEV) Antigen/IgG/IgM |
| DITR038 | Immunoglobulin A (Total IgA) |
| DITR039 | Immunoglobulin G (Total IgG) |
| DITR040 | Immunoglobulin M (Total IgM) |
| DITR041 | Prealbumin (PA) |
| DITR042 | Rubella IgG |
| DITR043 | Transferrin (TRF) |
